Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

NCT06792695 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06792695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
September 29, 2028
Enrollment
80 (estimated)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer